Skip to main
TTRX

TTRX Stock Forecast & Price Target

TTRX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Turn Therapeutics Inc. is positioned favorably in the biotechnology sector, primarily due to its proprietary PermaFusion technology, which enhances the efficacy and safety profiles of its drug candidates targeting dermatological conditions. The company’s strategic focus on moderate to severe eczema opens access to a significant addressable market of approximately 16.5 million individuals in the U.S., bolstered by favorable reimbursement dynamics and strong physician adoption rates. Additionally, opportunities for expansion into both eczema and onychomycosis markets could further increase revenue potential, particularly with the projected treatment pricing for onychomycosis set at $10,000 per course, reflecting a substantial therapeutic market need.

Bears say

Turn Therapeutics Inc operates within the clinical-stage biotechnology sector, focusing on dermatological and infectious disease products, yet it faces significant challenges that may negatively impact its stock outlook. The company's targeted conditions, such as eczema and onychomycosis, represent sizable markets with low treatment penetration, high recurrence rates, and modest cure rates, all of which suggest difficulties in achieving sustainable commercial success. Additionally, as a small-cap company, Turn Therapeutics is subject to heightened volatility and risks, which may deter potential investors despite the innovative nature of its proprietary PermaFusion technology.

TTRX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Turn Therapeutics Inc (TTRX) Forecast

Analysts have given TTRX a Strong Buy based on their latest research and market trends.

According to 1 analysts, TTRX has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Turn Therapeutics Inc (TTRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.